P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

December 2007

Features

Erythropoietic Therapy: Dosing Patterns and Calculated Cost Assessment for Pre-dialysis Chronic Kidney Disease Patients In a Managed Care Setting

In a comparison of two erythropoiesis-stimulating agents, drug costs were found to be lower for epoetin alfa than for darbepoetin alfa.
John J. Barron, PharmD, W. Daniel Grochulski, PhD, Samir H. Mody, PharmD, MBA, Brahim K. Bookhart, MBA, MPH, and R. Scott McKenzie, MD

Analysis and Opinion

FDA Bulks Up in 2008: Congress Injects Political Steroids; More Muscle for Drug Safety

Although far from perfect, the FDA Amendments Act gives the FDA more funds and authority, for example, in overseeing drug distribution and in forcing manufacturers to provide drug guides and to perform post-approval safety trials.
Stephen Barlas

Commentary

Welcome to the Blogosphere: Pharma Finally Joins the Conversation

There won’t be any juicy industry gossip or corporate intrigue, but Johnson & Johnson and GlaxoSmithKline hope that their new blogs will at least set the record straight about their companies and products.
Miriam Reisman

Meeting Highlights

Chemotherapy Foundation Symposium XXV: Innovative Cancer Therapy for Tomorrow

Topics include galiximab, bendamustine, and rituximab for hematological malignancies; pazopanib for renal cell cancer; trastuzumab and lapatinib for breast cancer; sorafenib/temozomide for melanoma; and IRX-2 for head and neck cancer
Marvin M. Goldenberg, PhD, RPh, MS

Meeting Highlights

European Cancer Conference and American College of Gastroenterology

Presentations cover advances in therapies for breast, prostate, and renal cancers and melanoma; adalimumab for patients with Crohn’s disease and fistula; and infliximab for the treatment of ulcerative colitis and colectomy.
Walter Alexander

Season’s Greetings: Thanks to Our Readers and Reviewers

Notice how we haven’t aged a bit in five years!

Departments

Editorial

Issuing an EDICT

David Nash, MD, MBA, explains how a new initiative encourages the participation of previously underrepresented groups in clinical trials, including the elderly, minorities, and rural residents.
David B. Nash, MD, MBA

Prescription: Washington

Congress Considers Antitrust Exemption for Pharmacies

Stephen Barlas discusses the Community Pharmacy Fairness Act, which might help independent pharmacies in their struggle to compete for customers being forced to use mail-order programs.
Stephen Barlas

Medication Errors

Safety and Patient-Controlled Analgesia Part 1: How Errors Occur

In Part 1 of a two-part series, Matthew Grissinger, RPh, FASCP, describes the factors that often contribute to the problem of unsafe patient-controlled analgesia.
Matthew Grissinger, RPh, FASCP

New Drugs/Drug News/New Medical Devices

From Abilify to Trasylol, P&T presents the latest information on FDA approvals, new indications, and industry updates.

Drug Forecast

Selegiline Orally Disintegrating Tablets (Zelapar)

The authors review selegiline orally disintegrating tablets (Zelapar) for Parkinson’s diseas­e.
Marilena S. Antonopoulos, PharmD, and Kristine S. Kim, PharmD